Figure 3.

Inhibition of MAPK pathway downregulates the activity of the CEACAM1 promoter.

CEACAM1 promoter was cloned upstream to firefly luciferase and co-transfected into the indicated melanoma cell lines together with a normalizing construct of Renilla luciferase. Empty vector served as negative control. Cells were treated for 2 days with DMSO, or 1 μM vemurafenib (VEM) or selumetinib (SEL). Relative promoter activity was calculated relative to the control (cells transfected with an empty vector and treated with DMSO). Figure shows the average results of four independent experiments. Significance was tested with ANOVA, ** and *** depict P value of <.01 and <.001, respectively.